Caspofungin was as effective as amphotericin B for invasive candidiasis.

P a t i e n t s 239 patients > 18 years of age who had ≥ 1 positive candida culture from blood or another sterile site in the past 4 days, and ≥ 1 clinical sign of infection in the past 2 days (fever, hypothermia, or hypotension) or signs of inflammation at a candida-infected site. Exclusion criteria included suspected endocarditis, osteomyelitis, or meningitis; and receipt of antifungal therapy > 2 days. 224 patients (94%) (median age 55 y, 56% men) were included in the modified intention-totreat analysis (documented diagnosis of invasive candidiasis and receipt of study treatment ≥ 1 d). All patients were included in the safety analysis.